Delivery Order SPE2DB22D1017-SPE2DB25FYPRV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $14,397.15 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen auto-injectors. The contract, finalized on August 12, 2025, with completion targeted for August 13, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open solicitation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injectors, valued at $6,777.99, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $29,756.49 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors. This firm fixed-price, competitively awarded delivery order was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order...
- The Defense Logistics Agency awarded a $22,738.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML). The contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025, and is being fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectors at a firm fixed price of $3,418.92. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 1, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $16,252.69 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on August 22, 2025, with an ultimate completion date of August 25, 2025. This non-set-aside, firm fixed price contract represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award is performed from the vendor's Conshohocken, Pennsylvania location, the company's corporate headquarters....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,072.57 on August 7, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectors (2 ml units). The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery order is a child contract under...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPRVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,931.71 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pen auto-injectors (2 mL) on September 2, 2025, with completion targeted for September 3, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems. The SPE2DX IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. This delivery order for DUPIXENT, a specialty pharmaceutical used in treating atopic dermatitis and other allergic conditions, reflects the company's ongoing role in supplying brand-name and generic medications through DLA's Medical Supply Chain to support Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 9/2/25 |